Oncolytics Biotech Company Profile

Aggregated data from the web about Oncolytics Biotech

Company Name	Oncolytics Biotech
Website	www.oncolyticsbiotech.com
Snippet	Innately Adaptive™ Oncolytics Biotech Inc. is developing REOLYSIN®, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to ...
Type	Public
Founded	1998
Website	www.oncolyticsbiotech.com
Industry	Biopharmaceutical
Products	REOLYSIN, a first-in-class intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors and hematological malignancies.
Traded as	TSX: ONC OTCQX: ONCYF
Key people	Matt Coffey Ph.D. - President, and Chief Executive Officer, Chief Operating Officer; Kirk Look, CA - Chief Financial Officer; Andres A. Gutierrez, M.D., Ph.D. - Chief Medical Officer; Andrew de Guttadauro, President, Oncolytics Biotech (U.S.) Inc.
Headquarters	Calgary, Alberta, Canada

Oncolytics Biotech is part of the Canada company list

Have a list of company names and need to update information? Use our Company Search tool.

Please note that Powrbot Inc does not own this content and cannot vouch for its accuracy, we simply aggregate public information for ease of research.

Want to update this profile? Please contact us here with a link to the public source verifying the edit.